UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 Delaware 27-5566468 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1776 Yorktown, Suite 550 Houston, TX 77056 77056 (Address of principal executive offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share NXL The Nasdaq Capital Market Warrants, exercisable for one share of Common Stock NXLIW The Nasdaq ...

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexal ...

HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") today announced publication of a landmark study titled, "Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer's Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Studyi" in the Journal of Alzheimer's Disease. This study builds on recent findings from Nexalin's Deep Intracranial Frequency Stimulatio ...

Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI) HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investi ...

HOUSTON, TX, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") today announced results from a clinical trial demonstrating improvements in memory and cognitive function for patients with mild Alzheimer's disease using its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology. The full results have been published in Alzheimer's Research & Therapy, one of the leading peer-reviewed journals in the field, further underscoring the scienti ...

HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, en ...

HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") announced its participation in a high-profile Congressional roundtable in North Carolina, focused on emerging virtual therapeutic options for opioid treatment. The event was hosted by the Breaking Barriers for Substance Use Recovery initiative and featured key stakeholders from across the healthcare and policy spectrum. The roundtable, held with Dr. Greg Murphy, U.S. Congressman represe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number: 001-41507 NEXALIN TECHNOLOGY, INC. (Exact name of Registrant as specified in its charter) | --- | --- | |---------------------- ...

Nexalin CEO Mark White Participates in Inaugural Meeting Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Substance Use Recovery brings together bringing together a broad cross section of leaders in the medical and science and technology industries to develop and formulate pioneering and innovative solutions to combat the opioid crisis. The organiz ...

Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Substance Use Recovery brings together bringing together a broad cross section of leaders in the medical and science and technology industries to develop and formulate pioneering and innovative solutions to combat the opioid crisis. The organization also advocates for the adoption of comprehensive po ...